Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Sensei Biotherapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/04/2023 |
SC 13G/A
| Cambrian BioPharma Inc reports a 14.6% stake in Sensei Biotherapeutics, Inc. |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/02/2023 |
SC 13D/A
| Apeiron Investment Group Ltd. reports a 0% stake in Sensei Biotherapeutics, Inc. |
| 05/23/2023 |
SC 13D/A
| Apeiron Investment Group Ltd. reports a 11.1% stake in Sensei Biotherapeutics, Inc. |
| 05/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Purchase Agreement, by and among Sensei Biotherapeutics, Inc., on the one hand, and Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd., on the other hand",
"Purchase Agreement, by and among Sensei Biotherapeutics, Inc., on the one hand, and Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd., on the other hand" |
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/20/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Investor presentation |
| 03/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/09/2023 |
SC 13D/A
| Apeiron Investment Group Ltd. reports a 11.2% stake in Sensei Biotherapeutics, Inc. |
| 03/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 03/07/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 02/14/2023 |
SC 13G/A
| Cambrian BioPharma Inc reports a 17% stake in Sensei Biotherapeutics, Inc. |
| 02/06/2023 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 12/08/2022 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 11/21/2022 |
SC 13D/A
| Apeiron Investment Group Ltd. reports a 11.2% stake in Sensei Biotherapeutics, Inc. |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Investor presentation, Quarterly results |
| 09/30/2022 |
8-K
| Quarterly results |
| 08/31/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
SC 13D
| Apeiron Investment Group Ltd. reports a 11.2% stake in Sensei Biotherapeutics, Inc. |
|
|
|